# HR+/HER2- Advanced Breast Cancer and Endocrine Resistance

> **NCT03322215** · PHASE2 · TERMINATED · sponsor: **Theodoros Foukakis** · enrollment: 42 (actual)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Fulvestrant
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03322215
- **Lead sponsor:** Theodoros Foukakis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-24
- **Primary completion:** 2021-04-30
- **Final completion:** 2023-10-31
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03322215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03322215, "HR+/HER2- Advanced Breast Cancer and Endocrine Resistance". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03322215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*